Galectin Therapeutics
GALT
66 hedge funds and large institutions have $12.3M invested in Galectin Therapeutics in 2023 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 10 increasing their positions, 16 reducing their positions, and 3 closing their positions.
200% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 3
96% more call options, than puts
Call options by funds: $45K | Put options by funds: $23K
10% more funds holding
Funds holding: 60 → 66 (+6)
3.24% less ownership
Funds ownership: 15.22% → 11.98% (-3.2%)
29% less capital invested
Capital invested by funds: $17.4M → $12.3M (-$5.09M)
38% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$360K |
| 2 |
6CM
683 Capital Management
New York
|
+$215K |
| 3 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$139K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$93.4K |
| 5 |
Jane Street
New York
|
+$65.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Osaic Holdings
Scottsdale,
Arizona
|
-$3.93M |
| 2 |
Millennium Management
New York
|
-$145K |
| 3 |
PNC Financial Services Group
Pittsburgh,
Pennsylvania
|
-$108K |
| 4 |
CCB
Cutter & Co Brokerage
Ballwin,
Missouri
|
-$23.3K |
| 5 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
-$22.5K |
GALT Hedge Fund Activity: Q4 2023 in Review
66 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Galectin Therapeutics (GALT) for Q4 2023, worth a combined $12.3M — down 29% from $17.4M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new GALT positions and 3 closed out — a net gain of 6 holders — while 10 added to existing stakes and 16 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $360K. The largest seller was Osaic Holdings, cutting an estimated $3.93M.
- 66 institutional investors held Galectin Therapeutics (GALT) as of Q4 2023, up from 60 in Q3 2023.
- Funds reported $12.3M of Galectin Therapeutics stock for Q4 2023, down 29% quarter-over-quarter.
- 9 funds opened new Galectin Therapeutics positions in Q4 2023 and 3 closed out, a net change of +6 holders.
- The largest Galectin Therapeutics buyer in Q4 2023 was Morgan Stanley, an estimated $360K added.
- The largest Galectin Therapeutics seller in Q4 2023 was Osaic Holdings, an estimated $3.93M sold.
Based on aggregated 13F filings for Q4 2023.